GlaxoSmithKline is to shed hundreds of U.S. commercial and research jobs, restructuring operations in its biggest market where drug sales are flagging. A total of 900 posts will be eliminated at GSK's Research Triangle Park site in North Carolina as drug research is consolidated in Philadelphia and in Stevenage, near London, according to a filing with the North Carolina Department of Commerce.